Researcher
Philippe Giron
- Research Expertise:
The implementation of fundamental molecular and cellular biology to improve clinical outcomes in oncogene driven lung cancer.
- Keywords:Medicine
- Disciplines:Cell signalling, Cell growth and development, Cancer biology, Cancer therapy
- Users of research expertise:
The implementation of fundamental molecular and cellular biology to improve clinical outcomes in oncogene driven lung cancer.
Affiliations
- Medical Genetics (Department)
Member
From1 Feb 2020 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Sep 2021 → 31 Jul 2023 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2020 → 31 Jul 2023 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2020 → 31 Dec 2020 - Clinical sciences (Department)
Member
From1 Jan 2016 → 31 Dec 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From7 Aug 2015 → 3 May 2022 - Clinical sciences (Department)
Member
From1 Oct 2014 → 31 Dec 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From21 Sep 2012 → 26 Jun 2014
Projects
1 - 1 of 1
- FWO-SB-beurs: Innovation through Combination: Identification of a novel combination therapy for improved treatment of EGFRFrom1 Jan 2016 → 31 Dec 2019Funding: FWO fellowships
Publications
1 - 10 of 17
- Peripheral precocious puberty in Li-Fraumeni syndrome(2023)
Authors: Sofie Ryckx, J De Schepper, Philippe Giron, Ken Maes, Freya Vaeyens, Kaat Wilgenhof, Pierre Lefesvre, Caroline Ernst, Kim Vanderlinden, Daniel Klink, et al.
- Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib(2023)
Authors: Carolien Eggermont, Gustavo J Gutierrez, Jacques De Greve, Philippe Giron
- Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells(2023)
Authors: Mathias Elsocht, Philippe Giron, Jacques De Greve, Steven Ballet
- The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer(2022)
Authors: Carolien Eggermont, Philippe Giron, Maxim Noeparast, Hugo Vandenplas, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Greve
- Exploiting genomic vulnerabilities in lung cancer for therapeutic targetting(2022)
Authors: Philippe Giron
Number of pages: 188 - Targeting USP13 mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in Non-Small Cell Lung Cancer(2021)
Authors: Philippe Giron, Carolien Eggermont, Maxim Noeparast, Hugo Vandenplas, Erik Teugels, Ramses G Forsyth, Olivier De Wever, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Greve
Pages: 2579-2593 - Structure-Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors(2021)
Authors: Mathias Elsocht, Philippe Giron, Laila Maes, Wim Versées, Gustavo J Gutierrez, Jacques De Greve, Steven Ballet
Pages: 1-40 - USP13 controls the stability of Aurora B impacting progression through the cell cycle(2020)
Authors: Mara Esposito, H Begum Akman, Philippe Giron, Maria De Los Angeles Ceregido Perez, Rogier Schepers, Luis Carlos Ramos Paez, Esther La Monaca, Jacques De Greve, Olivier Coux, Carl De Trez, et al.
Pages: 6009-6023 - In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis(2020)
Authors: Cabirou Mounchili Shintouo, Robert Adamu Shey, Derrick Neba Nebangwa, Kevin K Esoh, Nkemngo Francis Nongley, Joel Ebai Nguve, Philippe Giron, Léon Mutesa, Luc Vanhamme, Jacob Souopgui, et al.
Pages: 1-18 - CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition(2019)
Authors: Maxim Noeparast, Philippe Giron, Alfiah Noor, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Carolien Eggermont, Hugo Vandenplas, Bram Boeckx, Diether Lambrechts, Jacques De Greve, et al.
Pages: 5933-5941